Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have become a cornerstone therapy for managing type 2 diabetes mellitus (DM), heart failure (HF), and chronic kidney disease (CKD) due to their proven efficacy in glycemic control and decreasing cardiovascular events and heart failure hospitalizations as well as preventing the progression of kidney disease [1–3]. This evidence concerns the gene SLC5A2 and kidney disorder.